Is Aflac, Inc. overvalued or undervalued?
As of August 5, 2025, Aflac, Inc. is considered very expensive with a high P/E ratio of 36 and other valuation metrics indicating overvaluation compared to peers like Progressive Corp. and MetLife, despite its strong long-term performance.
As of 5 August 2025, the valuation grade for Aflac, Inc. has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is overvalued based on its current metrics, with a P/E ratio of 36, a Price to Book Value of 4.84, and an EV to Capital Employed ratio of 4.75. In comparison, Progressive Corp. has a P/E of 18.83 and MetLife, Inc. has a P/E of 18.69, both indicating that Aflac is trading at a premium relative to its peers.Despite a strong performance over the long term, with a 5-year return of 185.71% compared to the S&P 500's 96.61%, Aflac's recent returns have lagged behind the index, particularly in the 1-year period where it returned -0.88% versus the S&P 500's 17.14%. This suggests that while the company has historically performed well, its current valuation may not be justified given its recent performance and comparison to industry peers.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
